Ascendant Dx Closes on $2M Financing to Develop Proteomic-based Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Ascendant Dx today said that it closed on a $2 million funding round, which will support clinical trials for and commercialization of its tears-based breast cancer detection test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.